Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

CRANBURY, N.J., May 16, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ended March 31, 2011.

Recent Highlights

  • Following a meeting with the U.S. Food and Drug Administration (FDA), Palatin submitted a revised protocol to the FDA for initiation of an at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for women with female sexual dysfunction (FSD). This Phase 2 trial for women with FSD is scheduled to start in the second quarter of calendar 2011.
  • Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development of an inhalation formulation.
  • Collaboration compounds licensed pursuant to Palatin's research collaboration and license agreement with AstraZeneca for treatment of obesity, diabetes and related metabolic syndrome have advanced to the clinical stage.
  • In March 2011 Palatin closed on an underwritten public offering resulting in net proceeds of $21.1 million, which should be sufficient to fund projected operations through calendar year 2012.

  • Third Quarter Fiscal 2011 Financial ResultsPalatin reported a net loss of $3.8 million, or $(0.17) per basic and diluted share, for the quarter ended March 31, 2011, compared to a net loss of $2.0 million, or $(0.20) per basic and diluted share for the same period in 2010.  

    The increase in net loss for the quarter ended March 31, 2011, compared to the net loss for the same period last fiscal year, was primarily attributable to a decrease in revenue recognized und
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
    (Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
    (Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
    (Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
    Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
    ... International Daleco Corporation (Pink Sheets: ILDO) announces its ... joint venture company, ICAP Bio Organic, S. de R.L. ... and proprietary bio-organic catalyst compositions (BOCs) within Central America, Mexico ... renewable energy credit opportunities where available. , SIF ICAP ...
    ... , BEIJING, Oct. 27 /PRNewswire-Asia/ ... provider of biopharmaceutical products in China, announced today that,it ... vaccine, PANFLU.1, from,China,s Ministry of Industry and Information Technology ... is required to produce an,additional 5.19 million doses of ...
    ... YORK, Oct. 26 Reportlinker.com announces ... is available in its catalogue. , ... Pipeline Analysis and Competitive Assessment ... , In the nearly 35 ...
    Cached Biology Technology:Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean. 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 2Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 4Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 5Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 6Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 7Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 8
    (Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
    (Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
    (Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
    Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
    ... MIAMI -- The ability of marine reserves to replenish ... their ability to benefit shallow-water communities to thrive remains ... of Miami (UM) Rosenstiel School of Marine & Atmospheric ... has translated into positive impacts on coral communities in ...
    ... Industries LLC announced today that Oligonol, manufactured by Amino ... a recipient of the SupplySide West 2011 Scientific Excellent ... on Wednesday, October 12, 2011 in Las Vegas at ... technology providers with new ingredients or technologies, as well ...
    ... fish,s personality may determine how it is captured. This ... evolutionary and ecological consequences for affected fish populations, as ... Anglers fishing near rocky outcrops or in areas of ... catch timid fish, while those fishing in open water ...
    Cached Biology News: New study of Glover's Reef challenges whether corals will benefit from Marine Reserves' protection 2Oligonol receives Supplyside West 2011 scientific Excellence Award 2
    TUNEL Apoptosis Detection Kit...
    ... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
    HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
    Mouse Axl MAb (Clone 175128)...
    Biology Products: